Joining up more dots in the greatest crime in history
It's not a pretty picture!
It’s been a lot to take in
Subscribers will remember the dot joining exercise I’ve been sharing these last few weeks. I’m doing it in manageable chunks, so that people get a chance to absorb the enormity of what’s been going on—more for my sake than yours, as it’s a lot to take in!
Implicated so far, we have UK Government, in a post-Brexit world, desperate to become #1 in pharma R&D and prove to the world it was the right decision (which it wasn’t, IMHO).
Then we have the UK Government funded Cell & Gene Therapy Catapult (CGTC). I had personal involvement with the start of the Government’s love affair with Oxford BioMedica (OXB) in 2013. You can find out more here:
The love affair flourished, as courtship turned into full blown marriage between OXB and CGTC. At that time (2013), OXB was manufacturing a viral vector for clinical trials of Novartis’ Kymriah, which was approved by FDA in August 2017.
It costs $475,000 per treatment.
Note the safety warning on the labelling:
“WARNING: CYTOKINE…